Neuroendocrine tumours are extremely heterogeneous malignancies. Despite marked
heterogeneity in clinical course and prognosis, few biomarkers exist to help predict …

Tumour heterogeneity is a common phenomenon in neuroendocrine neoplasms (NENs)
and a significant cause of treatment failure and disease progression. Genetic and epigenetic …

Background For progressive metastatic medullary thyroid carcinoma (MTC), the available
treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a …

Sufficient expression of somatostatin receptor (SSTR) in well-differentiated neuroendocrine
tumours (NETs) is crucial for treatment with somatostatin analogues (SSAs) and peptide …

Neuroendocrine neoplasms (NENs) arise in secretory cells of the diffuse neuroendocrine
system, most commonly involving the gastrointestinal (GI) tract and pancreas. NENs include …

Abstract Context Pulmonary carcinoids (PCs) belong to neuroendocrine tumors that often
overexpress somatostatin receptors (SSTRs). This overexpression provides a molecular …

Objectives African Americans (AAs) have disproportionately higher incidence and lower
survival rates from pancreatic cancer compared with whites. Historically, this disparity has …

Simple Summary The need for prognostic and predictive biomarkers in pancreatic
neuroendocrine neoplasms (PNENs) is great. Overexpression of somatostatin receptors …

Objective The aim of this study was to develop an open-source and reproducible digital
quantitative analysis (DIA) of somatostatin receptor subtype 2a (SST2) staining in formalin …

Background: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR)
that can be targeted for therapy. Somatostatin receptor expression is routinely measured by …